vepdegestrant · Rigel Pharms · NDA 219835
Veppanu
Earliest generic entry, as listed · earliest of 2 marketed strengths
30 Jan 2038
Blocked by patent: US 10647698.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10647698 | substance, product | 30 Jan 2038 |
| US 10899742 | use U-4278 | 1 Dec 2037 |
| US 11597720 | substance, product, use U-4278 | 1 Dec 2037 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 1 May 2031 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219835 · 001 · RLD | tablet, oral | 100MG | 30 Jan 2038 |
| 219835 · 002 · RLD | tablet, oral | 200MG | 30 Jan 2038 |